Brain metastases pose a serious threat in EGFR-mutant NSCLC, with CNS-related mortality rates exceeding those observed in EGFR wild-type NSCLC (44.8% vs. 8.3%) [284]. Here, EGFR is linked to non-small cell lung carcinoma.